Treatment group | No. of cats on day 0 | Â | Days post-treatment |
---|
0 | 7 | 14 | 21 | 28–30 | 40-45 | 56-60 | 82-86 |
---|
Fluralaner1 | 31 | Geomean flea count3 | 11.4a,x | 0.4b,y | 0.3b,y | 0.1b,y | 0.2b,y | 0.1b,y | 0.1b,y | 0.0b,y |
Range | (5–63) | (0–4) | (0–4) | (0–3) | (0–2) | (0–2) | (0–3) | (0–0) |
% control4 | Â | 96.6 | 97.3 | 99.3 | 98.5 | 99.5 | 99.2 | 100 |
% (#) cats with no fleas | 0.0a,x (0/31) | 69.0b,y (20/29) | 71.0b,y (22/31) | 93.5b,y (29/31) | 80.6b,y (25/31) | 93.5b,y (29/31) | 90.3b,y (28/31) | 100b,y (31/31) |
Selamectin2 | 29 | Geomean flea count3 | 12.7a,x | 2.6a,y | 3.2a,y | 3.6a,y | 2.8a,y | 0.8a,y | 1.1a,y | 1.1a,y |
Range | (5–44) | (0–23) | (0–29) | (0–50) | (0–35) | (0–14) | (0–11) | (0–8) |
% control4 | Â | 79.4 | 74.6 | 71.3 | 77.8 | 93.8 | 91.0 | 91.3 |
% (#) cats with no fleas | 0.0a,x (0/29) | 24.1a,y (7/29) | 28.6a,y (8/28) | 17.2a,x (5/29) | 17.2a,x (5/29) | 37.0a,y (10/27) | 44.4a,y (12/27) | 38.5a,y (10/26) |
- 1In the fluralaner group cats were treated once topically on day 0 (Bravecto® Topical solution; Merck Animal Health, Madison, NJ, USA)
- 2In the selamectin group cats were treated on day 0 and once between days 28–30 and 56–60 (Revolution®; Zoetis, Whippany, NJ, USA)
- 3Geometric mean numbers of fleas in comb counts
- 4{(Day 0 geometric mean animal area flea counts – day x geometric mean animal area flea counts) / day 0 geometric mean animal area flea counts)} × 100
- a,bGeometric mean flea counts in a column with unlike letter superscripts are significantly different (P < 0.001; │t│≥ 3.70)
- x,yGeometric mean flea counts in a row with unlike letter superscripts are significantly different from day 0 (P < 0.001; │t│≥ 7.14)
- a,bPercent of flea-free cats in a column with unlike letter superscripts are significantly different (P < 0.002; Fisher’s exact test)
- x,yPercent of flea- free cats in a row with unlike letter superscripts are significantly different from day 0 (P < 0.01; Fisher’s exact test)